Technological aspects of creating neopeptide vaccines

Personalized neoantigen vaccines are a group of individually designed cancer that enhance patients’ own antigen-specific immune responses. These include based on dendritic cells, DNA, mRNA and synthetic peptides. An analysis 98 clinical trials neoantigenic from the ClinicalTrials.gov database found peptide one most popular vaccines, accounting for about 50 % trials. They usually consist mixture long or short peptides, dissolved depending their properties in an appropriate solvent, adjuvant stabilizes increases effectiveness. The used immunoadjuvants formulation neopeptide Toll-like receptor agonists (poly-ICLC) granulocyte-macrophage colony-stimulating factor. development presents number distinctive challenges compared to other types vaccines. process should cover validate various steps development, production administration processes order maximize efficacy safety In technology 3 main stages can be distinguished: 1) screening identification neoepitopes using approaches computer prediction, co-immunoprecipitation, mass spectrometry cytotoxic experiments; 2) synthesis peptides by methods standard solid-phase chemistry; 3) actually obtaining vaccine preparation suitable storage, transportation patient. Taking into account specificity drug, manufacturing must carried out strictly according Good Manufacturing Practice with mandatory quality control intermediate finished products